Neoadjuvant Doxorubicin-Paclitaxel Combined Chemotherapy in Patients with Inoperable Stage III Breast Cancer: A Retrospective Cohort Study with 10 Years of Follow-Up in Vietnam

INTRODUCTION: The combination of doxorubicin and paclitaxel (AP) is widely used in our country for the neoadjuvant treatment of breast cancer as well as metastatic breast cancer. The AP regimen has shown promise as a neoadjuvant therapy for breast cancer that improves pathological complete response...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Duc Thanh, Bui, Lap Thanh, Nguyen, Chu Van, Do, Kien Hung, Tran, Giang Le, Do, Tu Anh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447719/
https://www.ncbi.nlm.nih.gov/pubmed/37289321
http://dx.doi.org/10.1007/s40487-023-00233-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447719/
https://www.ncbi.nlm.nih.gov/pubmed/37289321
http://dx.doi.org/10.1007/s40487-023-00233-8

Ejemplares similares